Upsher-Smith announced the launch of Qudexy XR (topiramate) extended-release capsules. Qudexy XR was approved in March 2014 as initial monotherapy in patients >10 years old with partial-onset seizures or primary generalized tonic-clonic seizures. Also, it was approved as adjunctive therapy in patients >2 years old with partial-onset seizures, primary generalized tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome.
Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.
RELATED: New Extended-Release Treatment Option for Epilepsy
Qudexy XR is available as 25mg, 50mg, 100mg, 150mg, and 200mg extended-release capsules in 30-, 90-, and 500-count bottles. All Qudexy XR capsules may be swallowed whole or sprinkled on a spoonful of food.
For more information call (800) 654-2299 or visit QudexyXR.com.